Oracle Life Sciences Connect—Mumbai

March 15, 2024

Why attend Oracle Life Sciences Connect?

With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.

Meet with your peers and gain perspective on industry trends from leading experts on artificial intelligence, cloud-based research, real-world evidence, innovative study-site selection/activation/analytics, and additional advances that are transforming and streamlining clinical and safety development.


Times shown in


Clinical Research & Innovation - Clinical Insight is the Gateway

  • Dr. Anil Pareek

    President, Medical Affairs and Clinical Research,
    Ipca Laboratories Ltd

Igniting Innovation: Oracle Accelerates Research to Improve Patient Outcomes

The cost of bringing new therapies to market is rising and clinical trials are becoming increasingly complex. Discover how Oracle combines deep clinical expertise, unique data and cutting-edge technology to deliver consultative, end-to-end solutions that empower clinicians and improve the well-being of patients globally.

  • Vadiraj Jamadagni

    Senior Director, Sales,
    ANZ & South Asia (India & ASEAN),
    Oracle Life Sciences

Impact of Artificial Intelligence on Pharma R&D - Game Changer or a new Bubble?

The rise of generative AI companies on the stock markets have created a craze amongst investors. While financial analysts & strategists insist that this is not a new bubble, Pharma R&D is cautiously optimistic about the huge potential it holds for expediting new drug development and accelerating clinical trials with an infusion from AI technology. Let us understand this new whirlwind tech looming large on the pharma horizon.

  • Dr. Dhananjay Bakhle

    Chief Innovator, DocBrane Consulting LLP

EHR to EDC Integration

It has been a long-standing industry challenge that 50-70% of data collected in EDC is being manually re-entered from EHR systems by site staff who would rather spend their time on patient care and patient safety. As a result of the need for duplicative data entry, nearly 20-25% of study costs are related to manual transcription, often adding up to three minutes per data point (on data entry, validation, correction). This leads to an average loss of $8 million per day. Powered by Cerner, Oracle is working to transform the way that healthcare data is transferred to clinical trial systems for clinical research. By intelligently extract healthcare data from EHR systems to fuel clinical trials, Oracle is focused on creating a seamless experience for life sciences stakeholders.

  • Jeyaseelan Jeyaraj (Jey)

    Senior Director, Solutions Consulting, Asia Pacific,
    Oracle Life Sciences

Artificial Intelligence in Pharmacovigilance (or) Use of technology in Pharmacovigilance

Application of Artificial Intelligence in pharmacovigilance means new methods to improve case management and monitoring the risk-benefit balance. AI is interesting whenever you want to automate repetitive tasks involved in Data Processing. AI also help you to identify situations similar to your current case that may suggest a potential signal. There are various Pharmacovigilance activities where AI can be useful: First: Identification of unreported cases by browsing Social Media. Secondly, Individual Case Safety Report (ICSR). From a quantitative stand point this is clearly the most important step, because AI can increase speed and quality of processing. However, from a value, AI can assist Signal Detection. Risk Management is clearly a key element where AI can improve your work.

  • Dr. Rajendra Kumar Kasi

    Vice-President and Global Head of Pharmacovigilance,
    Glenmark Pharmaceuticals Limited


Turn the Corner

  • Edsel Pereira

    Executive Vice President - Information Technology,
    Glenmark Pharmaceuticals Limited

Improving Patient Recruitment with the Learning Health Network

Inefficiencies in patient recruitment continue to be a prevalent challenge in clinical research and significantly impact all stakeholders of the life sciences industry. Approximately $1.9 billion is spent on recruitment annually and 48% of research sites enroll one or fewer patients for a given trial. Oftentimes, 72% of trial participants are already patients at the site and 28% are new patients. Strong site relationships, deep clinical research expertise, and robust technology is key to achieving better study feasibility and high confidence in the eligibility of enrolled participants.

  • Jeyaseelan Jeyaraj (Jey)

    Senior Director, Solutions Consulting, Asia Pacific,
    Oracle Life Sciences

Real Time Data Acquisition

Real Time Data Acquisition in Clinical Trial, The Past, present and future of Real Time Data Acquisition (RTDA) and Gains and Obstacles in execution of RTDA

  • Mandar Vaidya

    VP, Operations, DiagnoSearch Life Sciences

Refreshments and networking

NextGen Safety One

Oracle's Safety One Strategy, offerings and differentiators including how we are building an open, intelligent, cloud-based health platform with secure applications.

  • Firasatullah Syed

    Principal Solutions Consultant, Oracle Life Sciences

Panel Discussion: Real World Evidence in Safety

Future of PV leveraging advanced signal detection and safety case management with Real World Evidence (RWE) to achieve important healthcare outcomes. Finding new ways to improve the safety of medicinal products by combining real-world data sets containing anonymized, longitudinal records that expand the potential of safety signaling.

  • Moderator: Firasatullah Syed

    Principal Solutions Consultant, Oracle Life Sciences

  • Dr. Khokan Debnath,

    Senior General Manager (Head)
    Clinical Operations Regulatory Affairs
    and Pharmacovigilance (India and Emerging Markets),
    Medical Affairs, Wockhardt Ltd

  • Dr. Anju Agarwal

    Global Director,
    Global Patient Safety,
    Advanz Pharma

  • Geeta N. Shanbhag

    Vice President – Pharmacovigilance & Medico-regulatory Affairs,
    Ipca Laboratories Ltd

  • Dr. Girish Sane,

    Section Head of Pharmacovigilance,
    Macleods Pharmaceuticals Limited

Patient-powered approach to trial design

  • Neeyor Bose

    Associate Principal, Real World Evidence, Oracle Life Sciences


Welcome, I'm your host

Puneet Walia
Puneet Walia Sales Director, West
  • Send an email
  • Connect on LinkedIn

  • Event location
    Jio World Convention Centre
    (Please enter via Gate 20/ Canopy G)
    Level 2, Meeting Suite 204 A & B
    Jio World Centre, G Block,
    Bandra Kurla Complex,
    Bandra East, Mumbai,
    Maharashtra 400098, India

Explore Oracle Life Sciences solutions and resources.